FDA
-
-
-
-
-
-
-
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
-
-
-
-
-
-
-
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
-
-
-
-
-
-
-
Regulus Therapeutics (RGLS) Reports Positive Topline Data from the Second Cohort in Phase 1b Trial of RGLS8429
-
-
-
-
-
-
-
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
-
-
-
-
-
-
Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
-
-
-
-
-
-
-
UPDATE: Cantor Fitzgerald Starts Regulus Therapeutics (RGLS) at Overweight
-
-
-
-
-
-
-
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program
-
322,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

